Factor V Leiden and the Risk for Venous Thromboembolism in the Adult Danish Population
- 2 March 2004
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 140 (5) , 330-337
- https://doi.org/10.7326/0003-4819-140-5-200403020-00008
Abstract
Odds ratios for venous thromboembolism (deep venous thrombosis and pulmonary embolism) derived from case–control studies range from 3 to 16 for heterozygotes compared with noncarriers and up to 79 for homozygotes compared with noncarriers. To estimate risks for venous thromboembolism in the adult Danish population according to factor V Leiden genotype. Cohort study with 23 years of follow-up. Adult Danish population. 9253 randomly selected individuals. Hospitalization and death from venous thromboembolism, factor V Leiden genotype, and additional thromboembolic risk factors. Adjusted hazard ratios in heterozygotes and homozygotes compared with noncarriers were 2.7 (95% CI, 1.8 to 3.8) and 18 (CI, 4.1 to 41) for venous thromboembolism overall, 2.4 (CI, 1.3 to 3.8) and 22 (CI, 0 to 60) for deep venous thrombosis, and 3.0 (CI, 1.7 to 4.9) and 11 (CI, 0 to 33) for pulmonary embolism. The lowest absolute 10-year risks for venous thromboembolism in factor V Leiden heterozygotes and homozygotes—0.7% (CI, 0.5% to 1.0%) and 3% (CI, 1% to 8%)—were found in nonsmokers younger than 40 years of age with a body mass index below 25 kg/m2; the corresponding highest risks—10% (CI, 7% to 14%) and 51% (CI, 13% to 100%)—were found in smokers older than 60 years of age with a body mass index above 30 kg/m2. Hazard ratios for venous thromboembolism in factor V Leiden heterozygotes and homozygotes compared with noncarriers in the adult Danish population were approximately 3 and 18, respectively. The simultaneous presence of smoking, obesity, and old age resulted in absolute 10-year thromboembolic risks of 10% in heterozygotes and 51% in homozygotes.Keywords
This publication has 23 references indexed in Scilit:
- Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analysesBlood, 2002
- Genetic risk factors of venous thrombosisHuman Genetics, 2001
- Factors V Leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosisThe American Journal of Medicine, 2001
- Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolismBritish Journal of Haematology, 2000
- Frequent factor II G20210A mutation in idiopathic portal vein thrombosisGastroenterology, 1999
- Increased Risk for Venous Thrombosis in Carriers of the Prothrombin G→A20210 Gene VariantAnnals of Internal Medicine, 1998
- Factor V Leiden Prevalence in Venous Thromboembolism PatientsChest, 1997
- The Risk of Recurrent Venous Thromboembolism in Patients with an Arg506→Gln Mutation in the Gene for Factor V (Factor V Leiden)New England Journal of Medicine, 1997
- World distribution of factor V LeidenThe Lancet, 1995
- Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy MenNew England Journal of Medicine, 1995